All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
CRP levels as a predictor of allogeneic transplant outcomes
Lia Minculescu and colleagues from Copenhagen University Hospital Rigshospitalet in Denmark conducted a retrospective study of allogeneic transplant patients to investigate whether C-reactive protein (CRP) levels drawn at time of graft-versus-host disease (GvHD) diagnosis can predict resistance to steroid therapy.
CRP is a protein made by the liver, which is released into the bloodstream as a response to tissue injury, infection or other inflammatory triggers. The study hypothesis is that co-existing causes of inflammation may aggravate GvHD. The study investigated both risk factors for development of GvHD and risk factors for development of steroid-refractory GvHD (SR-GvHD).
Key Findings:
- N = 461 total patients observed
- Acute GvHD (aGvHD): 44%
- Chronic GvHD (cGvHD): 49%
- SR-GvHD: 6%
- Risk factors for GvHD grade II–IV
- Age >53 years old vs < 53 years old: Odds Ratio (OR) = 0.67 (95% CI, 0.45–1.00), P = 0.05
- Non-myeloablative prep regimen vs myeloablative: OR = 0.54 (95% CI, 0.36–0.8), P = 0.02
- High-intensity (12 Gy) total body irradiation (TBI) vs other:OR = 0.35 (95% CI, 0.23–0.53), P = 0.001
- Peripheral blood stem cell product vs bone marrow, OR = 0.63 (95% CI, 0.41–0.98), P = 0.04
- CRP levels at GvHD diagnosis
- Liver: 104 mg/L (9–195)
- Skin: 36 mg/L (0–223)
- GI: 60 mg/L (0–253)
- Risk factors for SR-GVHD
- Grade II vs III GVHD: OR = 0.05 (95% CI, 0.02–0.14), P = <0.001
- Lack of visceral involvement: OR = 0.21 (95% CI, 0.09–0.51), P = 0.05
- CRP >10: OR = 1.5 (95% CI, 1.18–1.93), P = 0.001
- Patient age, preparatory regimen, TBI, donor-recipient gender mismatch, and graft source were not found to impact risk of SR-GvHD
- 5-year transplant related mortality (TRM) 50% greater if CRP >10 vs <10, P = 0.002
- GvHD-related mortality in SR-GvHD patients: 57.1%
This study showed that elevated CRP levels are associated with increased SR-GvHD and 5-year TRM rates. Grade III and visceral GvHD involvement also increased the risk of SR-GvHD. These are important indices that can help identify patients at highest risk of initial treatment failure to quickly navigate those patients toward second-line therapies.
References